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ABSTRACT
Objectives To compare the prevalence, clinical and
radiographic characteristics of psoriatic spondyloarthritis
(PsSpA) in psoriatic arthritis (PsA), with ankylosing
spondylitis (AS).
Methods A prospective single-centre cross-sectional
observational study recruited consecutive PsA and AS
cases. Participants completed outcome measures, and
underwent clinical examination, axial radiographic
scoring and HLA-sequencing. Multivariable analyses are
presented.
Results The 402 enrolled cases (201 PsA, 201 AS;
fulﬁlling classiﬁcation criteria for respective conditions)
were reclassiﬁed based upon radiographic axial disease
and psoriasis, as: 118 PsSpA, 127 peripheral-only PsA
(pPsA), and 157 AS without psoriasis (AS) cases. A
signiﬁcant proportion of patients with radiographic axial
disease had PsSpA (118/275; 42.91%), and often had
symptomatically silent axial disease (30/118; 25.42%).
Modiﬁed New York criteria for AS were fulﬁlled by 48/
201 (23.88%) PsA cases, and Classiﬁcation of Psoriatic
Arthritis criteria by 49/201 (24.38%) AS cases. pPsA
compared with PsSpA cases had a lower frequency of
HLA-B*27 (OR 0.12; 95% CI 0.05 to 0.25). Disease
activity, metrology and disability were comparable in
PsSpA and AS. A signiﬁcant proportion of PsSpA cases
had spondylitis without sacroiliitis (39/118; 33.05%);
they less frequently carried HLA-B*27 (OR 0.11; 95% CI
0.04 to 0.33). Sacroiliac joint complete ankylosis
(adjusted OR, ORadj 2.96; 95% CI 1.42 to 6.15) and
bridging syndesmophytes (ORadj 2.78; 95% CI 1.49 to
5.18) were more likely in AS than PsSpA. Radiographic
axial disease was more severe in AS than PsSpA
(Psoriatic Arthritis Spondylitis Radiology Index Score:
adjusted incidence risk ratio 1.13; 95% CI 1.09 to
1.19).
Conclusions In a combined cohort of patients with
either PsA or AS from a single centre, 24% fulﬁlled
classiﬁcation criteria for both conditions. The pattern of
axial disease was inﬂuenced signiﬁcantly by the presence
of skin psoriasis and HLA-B*27.
INTRODUCTION
Psoriatic spondyloarthritis (PsSpA) is a term that
can be used for spondyloarthritis (SpA) accompany-
ing psoriasis. PsSpA shares features of both psori-
atic arthritis (PsA) and ankylosing spondylitis
(AS),1–17 including axial arthritis, peripheral
arthritis and enthesitis. Only four studies have com-
pared the clinical characteristics of PsSpA and
AS,7 9 11 14 with the following reported to have
worse scores in AS compared with PsSpA: metrol-
ogy,11 14 occiput to wall distance14 and Schober’s
test of lumbar forward ﬂexion.7 9 14 Composite
indices of disease activity (Bath AS Disease Activity
Index; BASDAI),11 function (Bath AS Functional
Index; BASFI)11 and quality of life11 are reported
to be no different in AS and PsSpA.
Only four studies have compared the axial radio-
graphic characteristics of PsSpA and AS.2 7 9 11
Sacroiliitis appears to be commonly bilateral in AS
(even in early disease), but either unilateral or bilat-
eral in PsSpA.2 While Gladman et al7 demonstrated
a higher frequency of grade 4 sacroiliitis in AS
compared with PsSpA, the ﬁndings were not corro-
borated in another study.9 In AS, syndesmophytes
have been shown to be symmetrically distributed,2 9
progressing caudal to cranial, and with a primarily
marginal rather than paramarginal shape.2 In PsSpA,
syndesmophytes appear to progress randomly along
the spine,2 9 with equal frequency of marginal and
paramarginal syndesmophytes.2 9 Radiographic
severity appears to be worse in AS than in PsSpA, as
measured by the Bath AS Radiology Index,9 11 and
number of syndesmophytes.7
Since the ﬁndings of these studies have not been
entirely consistent, we sought to: (1) determine the
prevalence of PsSpA in a spondyloarthritis (PsA
and AS) cohort; (2) compare the clinical character-
istics of PsSpA with both pPsA and AS; (3) compare
the radiographic axial characteristics of PsSpA
and AS.
METHODS
A prospective single-centre cross-sectional observa-
tional study (Axial Disease in Psoriatic Arthritis
study) was conducted (2012–2013) at a secondary
care teaching hospital attended by 600 patients
with PsA and 750 patients with AS for ongoing
clinical care. Consecutive patients, aged ≥18 years,
attending dedicated PsA and AS clinics were invited
to participate, aiming to enrol 200 PsA and 200 AS
cases. Study inclusion criteria included either: a
diagnosis of PsA fulﬁlling the Classiﬁcation of
Psoriatic Arthritis (CASPAR) criteria18 19 in those
attending the PsA clinic; or a diagnosis of AS
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fulﬁlling the 1987 modiﬁed New York (mNY) diagnostic criteria
for AS20 in those attending the AS clinic.
Clinical assessment
Participants completed patient reported outcome measures vali-
dated for use in PsSpA, including: BASDAI,21–23 BASFI,14 24
Health Assessment Questionnaire Disability Index (HAQ),25 26
and Ankylosing Spondylitis Disease Activity Score
(ASDAS).22 23 27 Participants were questioned by a rheumatolo-
gist (DRJ) for a current or past history of: inﬂammatory axial
symptoms (Assessment of Spondyloarthritis Society deﬁn-
ition28); extra-articular manifestations including dactylitis, per-
ipheral enthesitis, chest wall pain, uveitis and inﬂammatory
bowel disease (IBD); family history in ﬁrst-degree relatives of
SpA, psoriasis, uveitis and IBD; tobacco smoking; synthetic
disease modifying antirheumatic drug (sDMARD) use; biologic
DMARD use; age at psoriasis symptom onset and diagnosis;
and age at arthritis symptom onset and diagnosis. Data were
veriﬁed using case notes.
All participants were examined by a rheumatologist (DRJ)
using these clinical examination indices: Bath Ankylosing
Spondylitis Metrology Index (BASMI),29 chest expansion, Leeds
Enthesitis Index (LEI),30 68 tender joint count,31 66 swollen
joint count (SJC),31 Psoriasis Area and Severity Index (PASI),32
modiﬁed Nail Psoriasis Severity Index (mNAPSI),33 and body
mass index (BMI).
Laboratory testing
Blood samples were taken for HLA-B typing and high-sensitivity
C reactive protein testing. All subjects were typed for HLA–B
alleles by a Sanger sequence-based method,34 except that the
PCR reactions were carried out using a nested two-stage
method,35 involving the heterozygous ampliﬁcation of exon-2,
intron-2 and exon-3 of HLA–B and HLA–C. Allele assignment
was performed using SeqScape software (V.2.5; Applied
Biosystems) and a library compiled from the current
ImMunoGeneTics database.36 Allele designations are those
recommended by the WHO nomenclature committee, and
which separates locus, allelic group and allelic type by an aster-
isk and colons.36 Allele frequencies were directly enumerated.
Axial radiographic scoring
In keeping with previous publications,37 38 inﬂammatory radio-
graphic axial disease (RAD) was deﬁned in PsSpA cases as the
presence of: New York criteria sacroiliitis (unilateral grade ≥3
or bilateral grade ≥2 sacroiliitis on pelvic radiograph) and/or ≥1
marginal/paramarginal syndesmophyte(s) of the cervical and/or
lumbar spine.
The most recent axial radiographs of all participants were
scored, blinded to clinical diagnosis, using two validated axial
radiographic scoring tools for PsA; the Psoriatic Arthritis
Spondylitis Radiology Index (PASRI)39 and the modiﬁed Stoke
Ankylosing Spondylitis Spinal Score (mSASSS).40 The hospital’s
clinical protocol ensures that all PsA and AS cases have plain
radiographs of their cervical spine (lateral in extension), lumbar
spine (anteroposterior and lateral) and pelvis (anteroposterior)
performed at least once during their care. Therefore radiographs
were not at ﬁxed time points relative to the research assessment.
Studies in AS report a very slow rate of axial radiographic pro-
gression (mean 1.3 unit/year; SD 2.5).41 As no data exist for
PsSpA, a pilot study was undertaken to estimate this rate in
PsSpA. Sequential axial radiographs were scored of 22 patients
with PsSpA attending the hospital over a period spanning 2–31
years. mSASSS progression in PsSpA was only 0.6 units/year,
justifying the use of historic radiographs (≤10 years old) with
prospective clinical data in this study.
Axial radiographic scoring reliability exercise and reading
strategy
Two raters (DRJ and AN) underwent training in axial radio-
graphic scoring by an experienced consultant musculoskeletal
radiologist (GR). A broad-based horizontal morphology with
adjacent degenerative features (intervertebral disc degeneration
and/or end plate changes) were deemed to be a degenerative
osteophyte. A thorn-like angulated morphology without adja-
cent degenerative features was deemed to be an inﬂammatory
syndesmophyte. Ten random cases (ﬁve PsA, ﬁve AS) were
selected from the cohort and scored independently by DRJ, AN
and GR (the ‘gold-standard’ rater) using the PASRI and
mSASSS, to assess inter-rater reliability. The same 10 cases were
scored again a month later to assess intrarater reliability. Axial
radiographs of the cohort were scored by two raters (DRJ and
AN) using the PASRI and mSASSS. All equivocal cases were dis-
cussed with GR before ﬁnal classiﬁcation.
Statistical analysis
Data were analysed using STATA V.12.1 (2011 Texas, USA).
Inter-rater and intrarater reliability was tested using the intra-
class correlation coefﬁcient (ICC). Univariable and multivariable
analyses were performed using the χ2 test, independent
Student’s t-test, Mann-Whitney U test, logistic regression, linear
regression, Poisson regression for non-normally distributed
count data, and zero-inﬂated Poisson regression for non-
normally distributed count data with an excess of zero values, as
appropriate. Reverse stepwise regression was used to adjust for
signiﬁcant covariates, including: sex; age and disease duration at
clinical assessment; age and disease duration at radiographic
assessment; current or past history of sDMARD use, antitumour
necrosis factor-α (anti-TNF) use and smoking; BMI and
HLA-B*27 status. The α-level for statistical signiﬁcance was
0.05.
Ethical considerations
The study was performed with ethical approval by Frenchay
Regional Ethics Committee, written consent from participants,
and in accordance with the Declaration of Helsinki.
RESULTS
The study enrolled 402 participants (201 PsA, 201 AS) and
there were no missing clinical data. Complete axial radiographs
were available for 392/402 (97.5%) participants; 10 PsA cases
with incomplete radiographs to determine RAD, were assumed
to have peripheral-only PsA (pPsA). The participants were
reclassiﬁed as: PsSpA (n=118; 29.35%) based upon psoriasis
(past/present) and RAD; pPsA (n=127; 31.60%) based upon
psoriasis (past/present), peripheral arthritis and no RAD; and
AS (n=157; 39.05%) based upon mNY criteria for AS20 and no
psoriasis (past/present). A substantial proportion of patients
with RAD had PsSpA (118/275; 42.91%).
Fulﬁlment of CASPAR, mNY and ASAS criteria
Forty-eight of 201 (23.88%) participants with PsA attending the
PsA clinic (all fulﬁlling CASPAR) also fulﬁlled mNY criteria for
AS. Forty-nine of 201 (24.38%) participants with AS attending
the AS clinic (all fulﬁlling mNY criteria) also fulﬁlled CASPAR
criteria for PsA. Although a lack of MRI data prevented us from
fully applying the ASAS classiﬁcation for axial SpA across our
cohort, we did ﬁnd that 157/157 (100%) of AS cases, 85/118
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(72%) of PsSpA cases and 9/127 (7%) of pPsA cases fulﬁlled
ASAS criteria for axial SpA by either or both clinical-only or
radiographic imaging streams.
Sociodemographic, treatment, laboratory and genetic
characteristics
PsSpA, pPsA and AS cases were broadly similar in terms of age,
disease duration, treatment and other sociodemographic
characteristics (tables 1 and 2). Any differences were adjusted
for in the multivariable models. HLA-B*27 alleles (mainly
HLA-B*27:05:02) were present in 9/127 (7.09%) pPsA, 47/118
(39.83%) PsSpA and 140/157 (89.17%) AS cases (table 1).
Compared with PsSpA cases, the presence of HLA-B*27 was sig-
niﬁcantly more likely in AS ( OR 12.44; 95% CI 6.67 to 23.22,
p<0.001) and signiﬁcantly less likely in pPsA (OR 0.12; 95%
CI 0.05 to 0.25, p<0.001).
Clinical predictors of PsSpA occurrence in PsA cases
Compared with pPsA cases, PsSpA cases had signiﬁcantly
younger age at arthritis symptom onset (median 37.98 years vs
31.27 years, p=0.01) (table 2). Male PsA cases were no more
likely than female cases to have PsSpA (adjusted OR, ORadj
1.48; 95% CI 0.87 to 2.52, p=0.18).
Patient-reported outcome measures
Inﬂammatory axial symptoms
A history (past/present) of inﬂammatory axial symptoms was
present in 77/127 (60.63%) pPsA, 88/118 (74.58%) PsSpA and
156/157 (99.36%) AS cases (table 3). Of note, 30/118 (25.42%)
PsSpA cases (with RAD by classiﬁcation) denied a history of
inﬂammatory axial symptoms. AS cases were signiﬁcantly more
likely to report inﬂammatory axial symptoms (history/current)
than PsSpA cases (ORadj 2.76; 95% CI 1.62 to 4.71, p<0.001
and ORadj 28.45; 95% CI 3.65 to 221.74, p=0.001, respect-
ively) (table 3). pPsA cases were signiﬁcantly less likely to have
current inﬂammatory axial symptoms (ORadj 0.57; 95% CI 0.34
to 0.96, p=0.03) than PsSpA cases, especially of the thoracic
spine (ORadj 0.48; 95% CI 0.26 to 0.88, p=0.02) and buttocks
(ORadj 0.38; 95% CI 0.20 to 0.71, p=0.003).
Personal history of extra-articular manifestations and family
history
pPsA cases were signiﬁcantly less likely to have a history of IBD
than PsSpA cases (ORadj 0.12; 95% CI 0.03 to 0.55, p=0.01)
(table 3). AS cases were signiﬁcantly less likely to have a history
of dactylitis than PsSpA cases (ORadj 0.18; 95% CI 0.07 to
0.42, p<0.001). Family history of SpA, psoriasis, uveitis and
IBD were no different between groups.
Composite clinical indices
Disease activity, as measured by ASDAS, was frequently high
(2.1–3.4) or very high (≥3.5) in both PsSpA (64/118; 54.24%)
and AS (80/157; 50.96%), with no statistically signiﬁcant dif-
ference between diseases. Similarly, in both PsSpA and AS
cases, BASDAI indicated active (≥3.5 units42) disease (median
3.60 vs 3.20), with no signiﬁcant statistical (adjusted incidence
risk ratio, IRRadj 1.03; 95% CI 0.92 to 1.17) or clinical
(minimum clinically important difference, MCID of 1 unit in
AS43) difference between diseases. Patient global assessment of
axial disease activity (PaGA) in both PsSpA and AS indicated
active (≥4 cm) disease, with no statistically signiﬁcant differ-
ences between diseases (median 3 cm vs 3 cm).
Function, as measured by the BASFI, was poorer in AS com-
pared with PsSpA (median 3.90 vs 3.10), with a clinically
(MCID 0.7 units in AS43) and a statistically signiﬁcant difference
between diseases (IRRadj 1.17 per 0.7 unit increase; 95% CI
1.06 to 1.26, p=0.002). No statistically signiﬁcant differences
in disability, as measured by the HAQ (MCID 0.35 units in
PsA44), was demonstrated between PsSpA and AS (IRRadj 1.04
per 0.35 unit increase; 95% CI 0.90 to 1.19), or PsSpA and
pPsA (IRRadj 1.09 per 0.35 unit increase; 95% CI 0.95 to 1.26).
Clinical examination indices
Peripheral examination indices
Nail disease severity, measured using the mNAPSI, was signiﬁcantly
lower in pPsA than PsSpA (IRRadj 0.90 per unit increase; 95% CI
0.83 to 0.97, p=0.01). More speciﬁcally, nail onycholysis severity
was signiﬁcantly lower in pPsA than PsSpA (IRRadj 0.84 per unit
increase; 95% CI 0.74 to 0.95, p=0.01). pPsA and PsSpAwere no
different in terms of SJC, enthesitis severity (LEI) or psoriasis sever-
ity (PASI). Enthesitis severity (LEI) was higher in AS than PsSpA
(IRRadj 1.33; 95% CI 1.02 to 1.74, p=0.04).
Axial metrology
Axial metrology measured using the BASMI was no different in
AS and PsSpA (IRRadj 1.07 per unit increase; 95% CI 0.95 to
1.21). However, tragus to wall distance (adjusted mean differ-
ence 2.00 cm; 95% CI 0.58 to 3.42, p=0.006) and modiﬁed
Schober’s test (adjusted mean difference −0.65 cm; 95% CI
−1.14 to −0.15, p=0.01) were poorer in AS than in PsSpA
cases. Other BASMI subdomains and chest expansion were no
different in PsSpA and AS. Surprisingly, BASMI and its subdo-
mains were no different in PsSpA and pPsA cases.
Table 1 Sociodemographic, genetic and treatment characteristics of the PsSpA (n=127), AS (n=157) and pPsA (n=118) cases (categorical
variables)
PsSpA AS pPsA AS versus PsSpA pPsA versus PsSpA
n (%) n (%) n (%) OR 95% CI p Value OR 95% CI p Value
Men 74 (63) 118 (75) 66 (52) 1.80 1.07 to 3.03 0.03* 0.65 0.39 to 1.08 0.09*
Caucasian ancestry (patient-reported) 117 (99) 156 (99) 127 (100) – – – – – –
HLA-B*27 presence 47 (40) 140 (89) 9 (7) 12.44 6.67 to 23.22 <0.001* 0.12 0.05 to 0.25 <0.001*
Smoking ever 57/110 (52) 72/157 (46) 67/109 (61) 0.79 0.48 to 1.28 0.34* 1.49 0.87 to 2.56 0.15*
Synthetic DMARD use ever 53 (45) 26 (17) 83 (65) 0.24 0.14 to 0.42 <0.001* 2.33 1.39 to 3.85 0.001*
Anti-TNF use ever 53 (45) 59 (38) 47 (37) 0.74 0.45 to 1.20 0.22* 0.72 0.43 to 1.22 0.21*
*Continuity adjusted χ2 test.
Anti-TNF, antitumour necrosis factor; AS, ankylosing spondylitis.
DMARD, disease modifying antirheumatic drug; HLA, human leucocyte antigen; n, number/proportion; pPsA, peripheral psoriatic arthritis; PsSpA, psoriatic spondyloarthropathy.
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Axial radiographic comparison of PsSpA and AS cases
Excellent34 inter-rater (ICC ≥0.85) and intrarater (ICC ≥0.88)
reliability was achieved by raters for the PASRI, mSASSS and
regional subdomains.
Axial radiographic pattern
The predominant pattern of sacroiliitis in both AS (142/147;
96.60%) and PsSpA (65/79; 82.28%) cases was bilateral (table 4),
albeit statistically different (p=0.001) (table 4). Symmetrical grade
sacroiliitis was the predominant pattern in both PsSpA (60/79;
75.95%) and AS (119/147; 80.95%), with no difference between
diseases (p=0.65). There was no signiﬁcant difference between AS
and PsSpA in terms of the occurrence of spondylitis (cervical and/
or lumbar), cervical vertebrae spondylitis, cervical facet joint
fusion or lumbar vertebrae spondylitis.
Of 118 cases classiﬁed as PsSpA: 45/118 (38.14%) had sacroi-
liitis with spondylitis, 39/118 (33.05%) had spondylitis alone
and 34/118 (28.81%) had sacroiliitis alone. The majority of
Table 2 Sociodemographic and laboratory characteristics of the PsSpA (n=118), AS (n=157) and pPsA (n=127) cases (numerical variables)
PsSpA AS pPsA AS versus PsSpA pPsA versus PsSpA
Median (IQR) Median (IQR) Median (IQR) Mean diff Mean diff
Mean (SD) Mean (SD) Mean (SD) (95% CI) p Value (95% CI) p Value
Age at (years)
Clinical assessment 58.09 (11.42) 53.44 (13.61) 58.13 (11.71) −4.63 (−7.68 to −1.58) 0.003* −0.03 (−2.95 to 2.88) 0.98*
Arthritis onset 31.27 (21.06, 46.24) 20.00 (16.00, 26.00) 37.98 (28.37, 46.32) – – – 0.01†
Arthritis diagnosis 35.99 (27.27, 52.00) 29.00 (23.00, 38.00) 39.99 (29.70, 48.73) – – – 0.33†
Psoriasis onset 31.50 (17.50, 41.50) – 27.00 (16.00, 14.00) – – – 0.68†
Psoriasis diagnosis 33.00 (19.00, 43.00) – 30.00 (19.00, 46.00) – – – 0.20†
Disease duration at (years)
Recent axial radiograph 15.50 (7.00, 26.00) 19.00 (10.00, 29.00) 13.00 (6.00, 23.00) – 0.13† – 0.41†
Clinical assessment 18.00 (9.00, 27.00) 22.00 (10.00, 31.00) 15.00 (7.00, 26.00) – 0.13† – 0.34†
C reactive protein 3 (2, 7) 4 (1, 10) 2 (0, 5) 1.06 (0.99 to 1.12) 0.07‡ 0.79 (0.74 to 0.84) <0.0001‡
Body mass index (BMI) 29.52 (5.16) 29.92 (4.96) 29.69 (5.36) −1.60 (−2.21 to −0.84) 0.01* −0.18 (−0.62 to 0.51) 0.81*
*Two-tailed Student’s t-test.
†Mann-Whitney U test.
‡Poisson regression (adjusted for: sex, age, disease duration, anti-TNF use ever, synthetic DMARD use ever, and BMI).
Anti-TNF, antitumour necrosis factor; AS, ankylosing spondylitis; DMARD, disease modifying antirheumatic drug; Mean diff, mean difference; pPsA, peripheral psoriatic arthritis; PsSpA,
psoriatic spondyloarthropathy.
Table 3 Axial inflammatory symptoms, extra-articular manifestations and family history in PsSpA (n=127), AS (n=157) and pPsA (n=118) cases
PsSpA AS pPsA AS versus PsSpA pPsA versus PsSpA
n (%) n (%) n (%) ORadj 95% CI p Value ORadj 95% CI p Value
Inflammatory axial symptoms
Current
Spine or buttocks 65 (55) 133 (85) 54 (43) 2.76 1.62 to 4.71 <0.001* 0.57 0.34 to 0.96 0.03*
Ever (past/current)
Spine or buttocks 88 (75) 156 (99) 77 (61) 28.45 3.65 to 221.74 0.001* 0.69 0.38 to 1.25 0.22*
Cervical 71 (60) 132 (84) 54 (43) 1.82 0.94 to 3.55 0.08* 0.73 0.42 to 1.27 0.26*
Thoracic 50 (42) 114 (73) 27 (21) 2.20 1.23 to 3.92 0.01* 0.48 0.26 to 0.88 0.02*
Lumbar 70 (59) 149 (95) 58 (46) 6.75 2.82 to 16.16 <0.001* 0.82 0.47 to 1.43 0.48*
Buttocks 55 (47) 132 (84) 24 (19) 3.19 1.67 to 6.07 <0.001* 0.38 0.20 to 0.71 0.003*
Extra-articular manifestations (ever)
Dactylitis 37 (31) 8 (5) 50 (39) 0.18 0.07 to 0.42 <0.001* 1.09 0.62 to 1.93 0.76*
Enthesitis 56 (47) 58 (37) 59 (46) 0.70 0.43 to 1.14 0.15* 0.93 0.56 to 1.55 0.79*
Chest wall pain 52 (44) 102 (65) 34 (27) 1.21 0.70 to 2.19 0.52* 0.63 0.35 to 1.15 0.13*
Uveitis 31 (26) 84 (54) 11 (9) 1.44 0.79 to 2.62 0.24* 0.52 0.22 to 1.22 0.13*
Inflammatory bowel disease 13 (11) 15 (10) 2 (2) 0.85 0.36 to 1.98 0.70* 0.12 0.03 to 0.55 0.01*
Family history
Spondyloarthritis 25 (21) 52 (33) 16 (13) 1.26 0.67 to 2.34 0.47† 0.73 0.34 to 1.53 0.40†
Psoriasis 58 (49) 20 (13) 56 (44) 0.16 0.08 to 0.30 <0.001 0.79 0.46 to 1.36 0.40
Uveitis 7 (6) 37 (24) 4 (3) 2.27 0.94 to 5.51 0.07† 1.84 0.42 to 7.99 0.42†
Inflammatory bowel disease 9 (8) 17 (11) 11 (9) 1.57 0.59 to 4.17 0.37 1.10 0.42 to 2.90 0.84
*Multivariable reverse-stepwise logistic regression model (adjusted for potential covariates, including: sex, age at assessment, disease duration at assessment, HLA-B*27 status, synthetic
DMARD use ever, anti-TNF use ever, smoking ever and body mass index).
†Reverse-stepwise logistic regression model adjusted for HLA-B*27 status.
Anti-TNF, antitumour necrosis factor; AS, ankylosing spondylitis; DMARD, disease modifying antirheumatic drug; n, proportion; ORadj, adjusted OR; pPsA, peripheral psoriatic arthritis;
PsSpA, psoriatic spondyloarthropathy.
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PsSpA cases with spondylitis alone were symptomatic (22/39;
56.41%); although were less likely to be symptomatic than
PsSpA cases with sacroiliitis with or without spondylitis (66/79;
83.54%) (OR 0.26; 95% CI 0.11 to 0.61, p=0.002). Thoracic
spine radiographs, MRI and CT scans were available on 32/39
PsSpA cases with spondylitis alone, and none demonstrated
diffuse idiopathic hyperostosis (DISH), deﬁned as per the cri-
teria of Resnick.45
Correlation of radiographic pattern with HLA-B*27 status in
PsSpA cases
HLA-B*27 was present in 6/39 (15.38%) of PsSpA cases with
spondylitis alone, 11/34 (32.35%) of cases with sacroiliitis alone
and 30/45 (66.67%) of cases with both sacroiliitis and spondyl-
itis. Logistic regression (adjusted for sex, age and disease dur-
ation) demonstrated a signiﬁcantly increased probability for the
presence of HLA-B*27 in PsSpA cases with both sacroiliitis and
spondylitis, compared with spondylitis alone (ORadj 9.10; 95%
CI 3.01 to 27.47, p<0.001).
Axial radiographic morphology
AS cases were more likely than PsSpA cases to have complete
SIJ ankylosis (ORadj 2.96; 95% CI 1.42 to 6.15, p=0.004), ver-
tebral bridging syndesmophytes (ORadj 2.78; 95% CI 1.49 to
5.18, p=0.001), but not partial SIJ ankylosis, SIJ erosion, SIJ
sclerosis, vertebral non-bridging syndesmophytes or vertebral
erosions (table 4).
Axial radiographic severity
Axial radiographic severity measured using the PASRI (and
mSASSS) was lower in women compared with men in both
PsSpA (median 5.5 vs 7.0; IRRadj 0.62 per unit increase; 95%
CI 0.57 to 0.67, p<0.001) and AS cases (median 8 vs 18;
IRRadj 0.67 per unit increase; 95% CI 0.61 to 0.73, p<0.001).
Axial radiographic severity was higher in AS than PsSpA, as
measured by the PASRI (median 15 vs 6; IRRadj 1.13 per unit
increase; 95% CI 1.09 to 1.19, p<0.001) and the mSASSS
(median 10 vs 3; IRRadj 1.09 per unit increase; 95% CI 1.04 to
1.14, p<0.001). Severity in AS was also greater than PsSpA
when analysed by axial region: cervical vertebral PASRI (IRRadj
1.57 per unit increase; 95% CI 1.35 to 1.83, p<0.001), cervical
facet joint PASRI (IRRadj 1.47 per unit increase; 95% CI 1.08 to
1.99, p=0.01) and lumbar vertebral PASRI (IRRadj 1.42 per
unit increase; 95% CI 1.29 to 1.58, p<0.001).
Using the mSASSS in PsSpA, the cervical region was more
severely affected than the lumbar spine (IRRadj 1.54 per unit
increase; 95% CI 1.20 to 1.74, p<0.001), but similar in AS.
Vertebral osteoproliferative severity, as measured by the PASRI,
(bridging and/or non-bridging syndesmophytes) was higher in
AS than PsSpA (median 6 vs 2; IRRadj 1.31 per unit increase;
95% CI 1.09 to 1.57, p=0.004). Vertebral erosion severity was
no different in the two diseases.
DISCUSSION
Studies suggest a high degree of overlap between pPsA, PsSpA
and AS; but are few in number and frequently of small sample
size. We therefore sought to further deﬁne the similarities and
differences between these conditions, and whether these could
be explained by clinical and genetic parameters. Axial disease
was deﬁned radiographically, due to the robustness and reprodu-
cibility of doing so. Accordingly, a signiﬁcant proportion of PsA
cases were reclassiﬁed to the PsSpA phenotype, and found to
often be asymptomatic. Importantly, a quarter of PsA and AS
Table 4 Axial radiographic pattern and morphology in PsSpA (n=118) and AS (n=157) cases
PsSpA AS AS versus PsSpA
n (%) n (%) OR 95% CI p Value
Pattern
Radiographic
Sacroiliitis 79 (67) 157 (100) – – –
Spondylitis (cervical and/or lumbar) 84 (71) 109 (69) 0.94 0.52 to 1.69 0.83
Sacroiliitis pattern
Bilateral 65/79 (82) 142/147 (97) 6.14 2.08 to 18.15 0.001
Symmetrical grade 60/79 (76) 119/147 (81) 1.17 0.59 to 2.32 0.65
Spondylitis pattern
Cervical vertebrae 52/116 (45) 85 (54) 1.20 0.65 to 2.25 0.56
Cervical facet joint 29 (25) 60 (38) 1.48 0.81 to 2.72 0.20
Lumbar vertebrae 50/117 (43) 85 (54) 1.37 0.75 to 2.50 0.30
Morphology
Sacroiliac joint
Sclerosis bilaterally (grade 2) 6 (5) 9 (6) 1.75 0.56 to 5.48 0.34
Erosion (grade 3) 42 (36) 53 (34) 1.07 0.63 to 1.81 0.80
Partial ankylosis (grade 3) 25 (21) 46 (29) 1.08 0.56 to 2.10 0.81
Complete ankylosis (grade 4) 18 (15) 68 (43) 2.96 1.42 to 6.15 0.004
Vertebral
Erosion, n (%) 3 (3) 6 (4) 1.58 0.38 to 6.57 0.53
Non-bridging syndesmophyte 47 (40) 58 (37) 0.93 0.57 to 1.56 0.79
Bridging syndesmophyte 12 (10) 36 (23) 2.78 1.49 to 5.18 0.001
*Multivariate reverse-stepwise logistic regression model (adjusted as required for the following potential covariates: sex, age at radiographic assessment, disease duration at radiographic
assessment, HLA-B*27 status, anti-TNF use ever, synthetic DMARD use ever, smoking and BMI).
Anti-TNF, antitumour necrosis factor; AS, ankylosing spondylitis; BMI, body mass index; DMARD, disease modifying antirheumatic drug; PsSpA, psoriatic spondyloarthritis.
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cases were classiﬁable as the other disease using the currently
available classiﬁcation systems.
In PsSpA cases, spondylitis without sacroiliitis was common
and usually symptomatic. Our methods ensured we were not
scoring degenerative lesions as being inﬂammatory, and the thor-
acic imaging of these cases conﬁrmed that they did not simply
have DISH. Previous studies have shown similarly high preva-
lence of spondylitis without sacroiliitis,3 4 and proposed it as a
feature distinguishing PsSpA from AS.46 The differing preva-
lence of HLA-B*27 alleles in our radiographic subphenotypes of
PsSpA offers a unique insight, and implies aetiopathogenic dif-
ferences between sacroiliitis and spondylitis in PsSpA.
AS cases were more likely than PsSpA cases to have complete
SIJ ankylosis and bridging syndesmophytes. These features may
prove more useful than syndesmophyte shape47 to distinguish
PsSpA from AS. Unilateral or asymmetrical grade sacroiliitis,
reported to be characteristic of PsSpA,9 were not found in the
current study, possibly as we have a more established disease
cohort at a later stage of radiographic disease. We do plan to
explore the association between certain HLA-B alleles and their
haplotypes, with symmetry of sacroiliitis, as has recently been
described by Haroon et al.48
Previous studies have found clinical predictors for PsSpA
occurrence in PsA include: male sex,3 4 9 the presence of
HLA-B*27,15 nail dystrophy,15 higher number of radiographic-
ally damaged joints,15 high erythrocyte sedimentation rate,15
and longer disease duration, with axial disease being a late-onset
feature.8 12 The latter clinical predictor may explain much of
the variation in estimated prevalence of PsSpA in PsA cohorts,
as many studies have investigated PsA cases with relatively
recent onset disease, allowing insufﬁcient time for the PsSpA
phenotype to have fully expressed. We acknowledge that to
truly understand the natural history of axial disease in PsA, a
longitudinal inception cohort study is required. Predictors of
PsSpA occurrence in our PsA cohort included: the presence of
HLA-B*27, younger age at arthritis onset, higher nail onycholy-
sis severity, axial inﬂammatory symptoms and IBD. Onycholysis
may be a more speciﬁc marker of synovial-entheseal complex
inﬂammation, a process considered important in SpA pathogen-
esis,49 and giving further biological credence to our ﬁnding.
The presence of psoriatic nail disease has been shown in
another study to be a biomarker of higher systemic enthesopa-
thy burden and higher inﬂammation scores, measured using
ultrasound.50
PsSpA is not a clinically less impactful form of AS; measures
of disease activity (ASDAS, BASDAI and PaGA), disability
(HAQ) and metrology (BASMI) were high in both PsSpA and AS
cases, with no statistically signiﬁcant difference between groups.
Of note, 74% of PsSpA cases had peripheral arthritis, and ero-
sions were observed in 64% (48/75) of those with available
radiographs, hence the additional burden of peripheral joint
disease may have inﬂuenced at least some of these measures.
The reliability of our results is improved by a large sample
size, single-centre follow-up, excellent inter-rater reliability for
radiographic scoring, no missing clinical data, limited (<3%)
missing radiographic data and a single rheumatologist perform-
ing clinical assessments; the inter-rater reliability of clinical
assessments in PsA is known to be poor.51 A limitation of our
study was the lack of MRI, inclusion of which on all patients
would have made the study unfeasible, and introduced selection
bias if only analysed for some of the cohort. Quantitative radio-
graphic scoring with embedded morphological data improved
the study’s power to detect differences between groups.
Inclusion of comprehensive covariate data in multivariable
models allowed adjustment for potential confounders, in par-
ticular disease duration. Our ﬁndings are generalisable because
the study was conducted in a secondary care hospital taking
unselected PsA and AS referrals.
The impact of recall bias is likely curtailed by a similar magni-
tude and direction of effect in each SpA group. Unfortunately
the cross-sectional study design reduced the ability to entirely
adjust for: time-varying variables such as smoking, BMI and
medication use; and unmeasured confounders such as NSAID52
use, delayed diagnosis and physiotherapy. While anti-TNF
therapy may inhibit53 54 or have no effect55 56 on syndesmo-
phyte formation in AS, no data exist in PsSpA.
To conclude, this study indicates that PsSpA forms part of the
SpA spectrum, ﬂanked by pPsA and AS. In terms of most clinical
indices of disease activity, PsSpA has a similar disease burden as
AS, despite being less severe radiographically. This may be of
relevance in the development of future treatment guidelines.
Furthermore, PsSpA may represent a distinct endophenotype
inﬂuenced by factors related to the presence of psoriasis, psori-
atic nail disease and HLA-B*27 variants. In future work we plan
to use our data set to further explore whether genetic variants
are closely linked with more homogeneously deﬁned patterns of
disease.
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